anifrolumab (Saphnelo)
Jump to navigation
Jump to search
Indications
- treatment of moderate-to-severe systemic lupus erythematosus
- refractory discoid lupus erythematosus
Adverse effects
- nasopharyngitis
- upper respiratory tract infections
- bronchitis
- infusion-related reactions
* cytopenias & thrombotic events not observed
Mechanism of action
Notes
- manufacturer AstraZeneca
More general terms
References
- ↑ Walsh N Thumbs Up From FDA for Anifrolumab in Lupus. Wonderful news for the lupus community, expert says. MedPage Today August 2, 2021 https://www.medpagetoday.com/rheumatology/lupus/93856
- ↑ Shaw K, Sanchez-Melendez S, Taylor D et al Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus. JAMA Dermatol. Published online March 15, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36920401 https://jamanetwork.com/journals/jamadermatology/fullarticle/2802155